



ADDRESSING CHALLENGES
IGNITING SOLUTIONS

SUMMIT ON
CONTROVERSIES IN
PRECISION MEDICINE

BERLIN, GERMANY
13-15 NOVEMBER 2017

WHERE DO WE STAND IN DRUG DEVELOPMENT?



PrecisionMedicine.kenes.com



SUMMIT ON CONTROVERSIES IN PRECISION MEDICINE

BERLIN, GERMANY | 13-15 NOVEMBER 2017

The growing controversies inside precision medicine need addressing head-on for the field to fulfil its promise.

Precision medicine aims to individualise therapeutic interventions, based on OMICS data such as genomics, proteomics, metabolomics etc', profiling together with histopathological insights to the type, stage, and the grade of the disease, as well as on the potential response of a particular patient to a particular treatment regimen. With next generation sequencing technologies, it is now possible to identify all germline variants of an individual at an affordable cost and thus paving the way for clinicians to provide healthcare from an individual perspective. However, the data that correlate specific disease type, response to specific treatment, and adverse effects as a result of the treatment, are slow to come. There are also critical voices warning us of getting lost in Big Data and advocating a stronger role of physiological models and phenotypic data in drug R&D. Another dimension of this debate is related to the way many companies manage their precision medicine processes and strategies for developing a more agile approach in the field.

The Summit on Controversies in Precision Medicine, under the leadership of Professor Dan Peer, Director of Tel Aviv University Cancer Biology Research Center and Translational Medicine, will explore in a realistic, non-biased manner global issues facing the community (clinicians, scientists, pharmaceutical industries and patients) that wants to build on the promise of Precision Medicine. By using plenary talks, scientific debates, and discussions, we will look at future ways to increase the productivity of biopharmaceutical and clinical innovation, with examples in oncology and rare diseases.

This year's summit is titled, "Where do we stand in drug development?" to create a focused environment for quality and open scientific debate on the value and direction of the industry. With an interactive architecture, the event is designed to provide the participants with exciting opportunities to ignite solutions, network and innovate.

Become part of 150+ senior level attendees from leading industry companies, academia and government institutions who have put innovation in their pipeline.

If you are eager to explore strategies for addressing challenges and igniting solutions in Precision Medicine, join us this November in Berlin!

SUMMIT ON CONTROVERSIES IN PRECISION MEDICINE

BERLIN, GERMANY | 13-15 NOVEMBER 2017

MEET THE SCIENTIFIC ADVISORY BOARD



Dan Peer, Chair
*Professor, Director of
Tel Aviv University
Cancer Biology
Research Center &
Translational Medicine*



Christian Elze
*Senior Partner
Catenion*



Gianni Gromo
*MD PhD, Partner
Versant Ventures*



Michael Heuser
*Prof Dr, Heisenberg
Chair for Molecular
Therapies in Haematology,
Hannover Medical School*



Yelena Yesha
*PhD, Director, NSF
Center for Hybrid
Multicore Productivity
Research, University of
Maryland*

OUR GOALS

- To provide participants with tools to ignite solutions in their organisations.
- To create a focused environment for quality debate on the value and direction of precision medicine.
- To generate deep understanding of biology vs. clinical impact.
- To present the two sides of the same coin and spark the conversation between industry, academia and policy makers.
- To provide perfect networking opportunities for industry stakeholders, policymakers and academic counterparts.



WHO WILL BE ATTENDING?

Become part of 150+ senior level attendees from leading industry companies, academia and government institutions who have put innovation in their pipeline!



Biopharma &
Tech Executives



CROs & R&D
Leaders



Solution
Providers



Academic
Dept. Heads



Research
Teams



Gov. Innovators
& Investors



SUMMIT ON CONTROVERSIES IN PRECISION MEDICINE

BERLIN, GERMANY | 13-15 NOVEMBER 2017

Where Do We Stand In Drug Development?


Monday, 13 November 2017	
16:00-18:00	THE DEBATE: <u>CONTROVERSIES IN PRECISION MEDICINE</u> Moderators: Dan Peer, Christian Elze We will introduce why and how we are at point of controversies today. The opening debate will explore whether a genetic-driven approach just needs more time to produce results or whether we need to first invest more in a regulatory filtering of genetic variations. WELCOME FROM SUMMIT CHAIRPERSON Dan Peer Director, Tel Aviv University Cancer Biology Research Center and Translational Medicine, Tel Aviv, Israel Debaters: Richard Fitzgerald Director, Clinical Research Unit, RLUH, Liverpool, UK Denis Noble Emeritus Professor of Cardiovascular Physiology, Oxford, UK <u>Panel Discussion with Audience Questions</u>
18:00-19:00	PLENARY LECTURE: <u>BUSINESS PERSPECTIVE</u> How to bring precision medicine to fields outside of oncology, mendelian rare diseases and infection diseases. We will review what has worked or not worked to date and therefore factors we need to be considering in moving forward. We will hone-in on how to approach building more viable businesses in precision medicine. Speakers: Christian Elze Senior Partner Catenion, London, UK Robert Wasserman Chief Medical Officer at Northern Biologics, Toronto, Canada
19:00	<u>NETWORKING RECEPTION</u>



SUMMIT ON CONTROVERSIES IN PRECISION MEDICINE

BERLIN, GERMANY | 13-15 NOVEMBER 2017

	Tuesday, 14 November 2017
08:30-10:15	<u>PRECISION MEDICINE - THE PHARMACEUTICAL STANDPOINT</u> Pre-Disease Intervention: Bringing Precision Medicine from the Back End to the Front End of Diseases. We will focus on how industry perceives the current challenges in precision medicine and their outlook based on specific case studies. Speakers: Thomas Bock Chairman and Chief Executive Officer HeritX, Santa Monica, USA Ivan Diaz-Padilla Medical Director, Global Drug Development (Oncology), Novartis, Basel, Switzerland Ludwig Heesen Project Manager Clinical Studies, BioNTech, Mainz, Germany <u>Round Table Discussions</u>
10:15-10:45	<u>COFFEE BREAK, NETWORKING, EXHIBITION</u>
10:45-12:30	<u>PRECISION MEDICINE IN THE CLINIC - CLINICAL STANDPOINT</u> <i>Case Studies & Panel Discussion on the clinical benefit.</i> We will seek to understand when a precision medicine approach will be beneficial and when it is unlikely to be so. If we can increase our understanding, then we can better focus on increasing the efficiency of precision medicine based drugs. Chair: Michael Heuser Heisenberg Chair for Molecular Therapies in Hematology, Hannover Medical School, Hannover, Germany Speakers: Ido Wolf Head, Oncology Division, Tel Aviv Medical Center, Tel Aviv, Israel Michael Heuser Heisenberg Chair for Molecular Therapies in Hematology, Hannover Medical School, Hannover, Germany TBC <u>Round Table Discussions</u>



SUMMIT ON CONTROVERSIES IN PRECISION MEDICINE

BERLIN, GERMANY | 13-15 NOVEMBER 2017

12:30-13:30	<u>LUNCH, NETWORKING & EXHIBITION</u>
13:30-15:15	<u>PATIENT STRATIFICATION VIA GENOMICS/ EPI-GENOMICS IN CANCER</u> Through the power of genomics and epi-genomics, we are starting to see some success in patient stratification for treating cancer. However, we currently lack the necessary tools to fully process and analyse the data in many cases, such as when multiple patients' phenotype data does not correspond to shared genome level mutations. How can we improve our data and what next steps do we need in clinical informatics? Speakers: Erez Levanon Associate Professor at The Mina and Everard Faculty of Life Sciences, Bar-Ilan University Ramat Gan, Israel Manfred Dietel Full Professor and Director of the Institute of Pathology, University Hospital Charité, Berlin, Germany TBC Round Table Discussions
15:15-15:45	<u>COFFEE BREAK, NETWORKING, EXHIBITION</u>
15:45-17:30	<u>DEVELOPING NEW DELIVERY VEHICLES FOR PRECISION MEDICINE</u> Much of the potential of precision medicine rests on drug delivery strategies. What is achievable with current drug carriers and where do we need to focus in our current pipeline? How can precision medicine benefit from nanomedicine? And if the future of precision medicine lies in altering nucleic acid, then where do we need to focus our research to make it a reality? Speakers: Heinrich Haas Vice President RNA Formulation & Drug Delivery at BioNTech RNA Pharmaceuticals, Mainz, Germany James Taylor Co-founder, CEO at Precision NanoSystems, Inc., Vancouver, Canada Twan Lammers Head of department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, Germany



SUMMIT ON CONTROVERSIES IN PRECISION MEDICINE

BERLIN, GERMANY | 13-15 NOVEMBER 2017

	Round Table Discussions
17:30-18:45	THE FUTURE OF PRECISION MEDICINE FROM A REGULATORY STANDPOINT Regulatory agencies will present their view on the emerging field of precision medicine and what they are seeing as the needed criteria to ensure a fair and efficient approval process. Speakers: Khaled Bouri Science Advisor Office of Regulatory Science and Innovation, Food and Drug Administration, Silver Spring, USA TBC


Wednesday, 15 November 2017	
08:30-10:15	DISEASE SIGNATURE AND SMALL VS. BIG DATA IN PRECISION MEDICINE This session will review the challenges of operating without an aligned definition of disease signature. We will consider the amount of data we are processing, both small and big data, as well as whether we should be taking advantage of clinical trials to collect as much real-time physical and environmental data. Speakers: Mira Marcus-Kalish Director, International Research Affairs, Tel Aviv University Ramat Aviv, Tel Aviv, Israel Yelena Yesha Professor, Department of Computer Science and Electrical Engineering, University of Maryland, Baltimore County, USA Ancha Baranova Associate Professor, School of Systems Biology, George Mason University, Fairfax, USA Round Table Discussions
10:15-10:45	COFFEE BREAK, NETWORKING, EXHIBITION
10:45-12:30	HEALTH INFORMATICS How do we analyse complex diseases? Are computer-based solutions such as AI and machine learning the best solution



SUMMIT ON CONTROVERSIES IN PRECISION MEDICINE

BERLIN, GERMANY | 13-15 NOVEMBER 2017

	direction? What is their potential and limitations? And what future steps do we need in R&D to actualise such solutions? Speakers: Harsha Rajasimha Global Head, Life Sciences R&D, NTT DATA Inc., Washington, USA Gordon Broderick Director, Center for Clinical Systems Biology, NY, USA Edit Buzas Professor and Chair at Semmelweis University, Department of Genetics, Cell- and Immunobiology, Budapest, Hungary Round Table Discussions
12:30-13:30	LUNCH, NETWORKING, EXHIBITION
13:30-14:30	THE POWER OF PRECISION MEDICINE IN RARE DISEASE <i>Panel discussion: The Role of Foundations in Precision Medicine</i> The field of rare diseases is expanding to the point of more than 10,000 sub-diseases. There is a lack of single drugs suitable for enough of these sub-diseases, which has made the drug discovery process less financially attractive and riskier for pharma. The challenge for precision medicine is to develop a global drug solution where there is a common denominator. Where are we at and how can the market move forward? Panellists: Amylynne Volker Founder Nicholas Volker One In A Billion Foundation, USA Peter Kapitein President and Patient Advocate Inspire2Live, Amsterdam, Netherlands Janet Allen Director of Strategic Innovation at Cystic Fibrosis Trust, London, UK
14:30-16:15	NEW THERAPEUTIC MODALITIES FOR RARE DISEASE Is there potential for a new protein or messenger RNA that will fit all mutations and generate a global solution for a disease? Case studies on this and other novel approaches for treating rare diseases. Speakers: Dan Peer



SUMMIT ON CONTROVERSIES IN PRECISION MEDICINE


BERLIN, GERMANY | 13-15 NOVEMBER 2017

	Director, Tel Aviv University Cancer Biology Research Center and Translational Medicine, Tel Aviv, Israel Johnathan Knowles Chairman of The Board Of Directors at Immunocore Limited, Oxford, UK TBC Round Table Discussions
16:15-16:45	COFFEE BREAK, NETWORKING, EXHIBITION
16:45-17:30	CLOSING - SUMMARY & DISCUSSION Panel discussion on the next steps for precision medicine. Summary of where are the challenges and what are the potential solutions.

REGISTRATION INFORMATION

Fees apply to payments received prior to the indicated deadlines.
Fees exclude 19% VAT.

	Registration before and including 24 October 2017	Registration from 25 October 2017
<i>Commercial Participants</i>	€1590 + VAT	€1900 + VAT
<i>Academic Participants</i>	€670 + VAT	€800 + VAT
<i>Clinician Participants (HCPs)</i>	€670 + VAT	€800 + VAT
<i>Packages including Hotel</i>	Minimum 2 nights, 13-15 Nov €140 per night (single room) Incl. breakfast, VAT, city tax	n/a
<i>Discounts on registration fees (not incl. hotel)</i>	20% reduction for groups of over 3 participants	20% reduction for groups of over 3 participants



SUMMIT ON CONTROVERSIES IN PRECISION MEDICINE

BERLIN, GERMANY | 13-15 NOVEMBER 2017

For more information or group registration, please contact:

Maria Vasileva
Delegate Service Specialist



Tel. +359-2-808-2110
Email: reg_pmed17@kenes.com

SUPPORT & PARTICIPATE

You can choose from the packages below or from the list of opportunities below. Your level of support will be determined by your total contribution (including support opportunities and exhibition space). We would be pleased to discuss with you and customize a package to your needs.

Level of Support	PLATINUM	GOLD	SILVER
Total Contribution (+VAT*)	€ 20,000 +	€15,000	€8,000
BENEFITS:			
Speaker Presentation (30 min)	✓	✓	
Research / Product Theatre (15 min)	✓		✓
Roundtable Host (30 min)		✓	
Advertisement (in programme book)	✓	✓	
One Exhibition Counter	✓		✓
Full Registration(s)	2	1	
Delegate List (name and country)	✓	✓	✓



SUMMIT ON CONTROVERSIES IN PRECISION MEDICINE

BERLIN, GERMANY | 13-15 NOVEMBER 2017

Support Opportunities:	Price (+VAT*)
Speaker Presentation (30 min)	€10,000
Research / Product Theatre (15 min)	€5,000
Roundtable HOST (30 min)	€8,000
Mobile App	€20,000
Delegate Bags	€5,000 + provided in kind
Lanyards	€6,000 + provided in kind
Welcome/Networking Reception	€12,000
Branded Seats in Exhibition (50)	€8,000
Branded seat covers (in the session hall)	price upon request
Advertisement (inside page of programme book)	€2,000
Meeting Rooms/ Hospitality Suites	price upon request

INDUSTRY HUB €5,000

WE ARE OFFERING THE NEW HIGH COUNTER EXHIBITION BOOTHS

High counter with your branding and high chair

- Two Exhibitor Badges
- 100 word company/product profile in programme
- Cleaning of public areas and gangways
- Invitation to the Welcome Reception for registered exhibitors

Other furniture or electrical usage will not be included. All these services and other will be available to order in the Exhibitors' Technical Manual.

Larger exhibition spaces also available, upon request.

Contact us

to schedule a call, for more information and for bookings:

Nelly Dimitrova



Tel: +359 2 808 2110
Email: ndimitrova@kenes.com

SUMMIT ON
CONTROVERSIES IN
PRECISION MEDICINE

BERLIN, GERMANY | 13-15 NOVEMBER 2017

SEE YOU IN BERLIN!